Tratamiento de la enfermedad de Alzheimer. Rol de agentes neurotróficos

Abstract

Dementia and mainly Alzheimeŕs disease is a very serious and frequent clinical problem. So far, the pharmacological treatment with approved drugs has been essentially symptomatic. Although the aetiology of AD is not yet fully understood, new therapy approaches are primarily based on the amyloid hypothesis. Unfortunately the new drugs with amyloid target have had difficulties to show consistence in efficacy and safety. On the other hand, neurotrophic factors such as NGF and BDNF are small, versatile proteins that maintain survival and function to specific neuronal populations, for instance cholinergic neurons, on which they have a trophic and protective effect. Cerebrolysin is a peptidergic drug, approved for Alzheimeŕs disease in some countries, containing biologically active peptides that exerts nerve growth factor like activity and it has interesting data about pleiotropics properties of the compound. Some clinical trials with cerebrolysin have demonstrated cognitive and functional benefits when comparing with placebo. In a complex therapeutic scene appears necessary to explore with more clinical trials the neurotrophic way.